These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25032734)

  • 1. Identification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma.
    Nishimura K; Tsuchiya Y; Okamoto H; Ijichi K; Gosho M; Fukayama M; Yoshikawa K; Ueda H; Bradford CR; Carey TE; Ogawa T
    Br J Cancer; 2014 Aug; 111(4):799-806. PubMed ID: 25032734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of cisplatin-resistant factor by integration of transcriptomic and proteomic data using head and neck carcinoma cell lines.
    Inukai D; Nishimura K; Okamoto H; Sano R; Ueda H; Ota A; Karnan S; Hosokawa Y; Yoshikawa K; Suzuki S; Ueda R; Murotani K; Bradford CR; Ogawa T
    Nagoya J Med Sci; 2020 Aug; 82(3):519-531. PubMed ID: 33132436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma.
    Syed N; Chavan S; Sahasrabuddhe NA; Renuse S; Sathe G; Nanjappa V; Radhakrishnan A; Raja R; Pinto SM; Srinivasan A; Prasad TS; Srikumar K; Gowda H; Santosh V; Sidransky D; Califano JA; Pandey A; Chatterjee A
    Proteomics; 2015 Jan; 15(2-3):383-93. PubMed ID: 25327479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-cycle distribution and Thymidilate Synthatase (TS) expression correlate with 5-FU resistance in head and neck carcinoma cells.
    Ijichi K; Adachi M; Ogawa T; Hasegawa Y; Murakami S
    Anticancer Res; 2014 Jun; 34(6):2907-11. PubMed ID: 24922653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis.
    Mohapatra P; Shriwas O; Mohanty S; Ghosh A; Smita S; Kaushik SR; Arya R; Rath R; Das Majumdar SK; Muduly DK; Raghav SK; Nanda RK; Dash R
    JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
    Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
    Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposome encapsulated curcumin-difluorinated (CDF) inhibits the growth of cisplatin resistant head and neck cancer stem cells.
    Basak SK; Zinabadi A; Wu AW; Venkatesan N; Duarte VM; Kang JJ; Dalgard CL; Srivastava M; Sarkar FH; Wang MB; Srivatsan ES
    Oncotarget; 2015 Jul; 6(21):18504-17. PubMed ID: 26098778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitization of head and neck cancer to cisplatin through the use of a novel curcumin analog.
    Abuzeid WM; Davis S; Tang AL; Saunders L; Brenner JC; Lin J; Fuchs JR; Light E; Bradford CR; Prince ME; Carey TE
    Arch Otolaryngol Head Neck Surg; 2011 May; 137(5):499-507. PubMed ID: 21576562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin activates survival signals in UM-SCC-23 squamous cell carcinoma and these signal pathways are amplified in cisplatin-resistant squamous cell carcinoma.
    Aoki K; Ogawa T; Ito Y; Nakashima S
    Oncol Rep; 2004 Feb; 11(2):375-9. PubMed ID: 14719071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL.
    Bauer JA; Trask DK; Kumar B; Los G; Castro J; Lee JS; Chen J; Wang S; Bradford CR; Carey TE
    Mol Cancer Ther; 2005 Jul; 4(7):1096-104. PubMed ID: 16020667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma.
    Theile D; Gal Z; Warta R; Rigalli JP; Lahrmann B; Grabe N; Herold-Mende C; Dyckhoff G; Weiss J
    Cancer Biol Ther; 2014 Apr; 15(4):436-42. PubMed ID: 24448417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Livin enhances chemoresistance in head and neck squamous cell carcinoma.
    Yoon TM; Kim SA; Lee DH; Lee JK; Park YL; Lee KH; Chung IJ; Joo YE; Lim SC
    Oncol Rep; 2017 Jun; 37(6):3667-3673. PubMed ID: 28440463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment with 5-FU enhances cisplatin cytotoxicity in head and neck squamous cell carcinoma cells.
    Ijichi K; Adachi M; Hasegawa Y; Ogawa T; Nakamura H; Kudoh A; Yasui Y; Murakami S; Ishizaki K
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):745-52. PubMed ID: 18075740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of cisplatin-resistance related genes in head and neck squamous cell carcinoma.
    Yamano Y; Uzawa K; Saito K; Nakashima D; Kasamatsu A; Koike H; Kouzu Y; Shinozuka K; Nakatani K; Negoro K; Fujita S; Tanzawa H
    Int J Cancer; 2010 Jan; 126(2):437-49. PubMed ID: 19569180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
    Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
    Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
    Huang Z; Li H; Huang Q; Chen D; Han J; Wang L; Pan C; Chen W; House MG; Nephew KP; Guo Z
    Mol Carcinog; 2014 Oct; 53(10):777-86. PubMed ID: 23661500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
    Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
    J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer.
    Nör C; Zhang Z; Warner KA; Bernardi L; Visioli F; Helman JI; Roesler R; Nör JE
    Neoplasia; 2014 Feb; 16(2):137-46. PubMed ID: 24709421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer.
    Friedman J; Nottingham L; Duggal P; Pernas FG; Yan B; Yang XP; Chen Z; Van Waes C
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6568-78. PubMed ID: 18006756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing heat shock protein 27 decreases metastatic behavior of human head and neck squamous cell cancer cells in vitro.
    Zhu Z; Xu X; Yu Y; Graham M; Prince ME; Carey TE; Sun D
    Mol Pharm; 2010 Aug; 7(4):1283-90. PubMed ID: 20540527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.